Trial Profile

A NON-RANDOMIZED, OPEN LABEL, SAFETY AND EFFICACY STUDY EVALUATING KAMUVUDINE-8 (K8) FOR THE TREATMENT OF PATIENTS WITH GEOGRAPHIC ATROPHY

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Kamuvudine 8 (Primary)
Indications Dry macular degeneration
Focus Adverse reactions; Therapeutic Use
Acronyms K8 for GA

Most Recent Events

15 Jan 2025 According to an Inflammasome Therapeutics media release, company announced Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky
15 Jan 2025 Results published in the Inflammasome Therapeutics media release
05 Dec 2024 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com